PGENNasdaqPharmaceutical PreparationsFiscal year ends December 31
PRECIGEN, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$6.66+0.28 (+4.31%)
Close on Oct 19, 2026
- Market cap
- $2.76B
- P/E (TTM)
- –
- Dividend yield
- –
PRECIGEN, INC. revenue by segment
By business segment
| Revenue | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | TTM Q2 23 | TTM Q1 23 | TTM Q4 22 | TTM Q3 22 | TTM Q2 22 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exemplar | $3.93M | $3.93M | $3.89M | $4.31M | $5.36M | $6.15M | $6.64M | $7.36M | $8.44M | $12.02M | $13.85M | $14.96M | 100.0% | -26.8% |
| Biopharmaceuticals | – | – | – | – | – | $75.00K | $116.00K | $14.74M | $14.81M | $14.89M | $16.59M | $3.24M | – | – |
| Reportable Segments | – | – | – | – | – | – | – | $22.10M | $23.25M | $28.36M | $30.44M | $18.20M | – | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Precigen's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.